EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Dianthus Therapeutics's enterprise value is $443.49 Mil.
Dianthus Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $2.26 Mil. Therefore, Dianthus Therapeutics's EV-to-Revenue for today is 196.67.
The historical rank and industry rank for Dianthus Therapeutics's EV-to-Revenue or its related term are showing as below:
DNTH'
s EV-to-Revenue Range Over the Past 10 Years
Min: -42.94 Med: 50.76 Max: 124.69
Current: 196.67
During the past 3 years, the highest EV-to-Revenue of Dianthus Therapeutics was 124.69. The lowest was -42.94. And the median was 50.76.
DNTH's EV-to-Revenue is ranked worse than 87.99% of 1041
companies
in the Biotechnology industry
Industry Median: 8.07
vs DNTH: 196.67
Dianthus Therapeutics EV-to-Revenue Historical Data
The historical data trend for Dianthus Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Dianthus Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Dianthus Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dianthus Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dianthus Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Dianthus Therapeutics's EV-to-Revenue falls into.
Dianthus Therapeutics's current Enterprise Value is $443.49 Mil.
Dianthus Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dianthus Therapeutics's share price for today is $27.69.
Dianthus Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.30.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dianthus Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Dianthus Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Dianthus Therapeutics (Dianthus Therapeutics) Business Description
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is comprised of an experienced team of biotech and pharma executives who are leading the next generation of antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DNTH has been successfully added to your